• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Atea Pharmaceuticals Inc.

    6/20/25 5:16:20 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVIR alert in real time by email
    8-K
    false 0001593899 0001593899 2025-06-20 2025-06-20
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of report (Date of earliest event reported): June 20, 2025

     

     

    Atea Pharmaceuticals, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-39661   46-0574869

    (State or other jurisdiction of

    incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification Number)

    225 Franklin Street

    Suite 2100

    Boston, MA 02110

    (Address of principal executive offices) (Zip Code)

    (857) 284-8891

    (Registrant’s telephone number, include area code)

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.001 par value per share   AVIR   The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.07.

    Submission of Matters to a Vote of Security Holders.

    On June 20, 2025, Atea Pharmaceuticals, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). Holders of a total of 74,981,407 shares of the Company’s common stock were present in person or represented by proxy at the Annual Meeting, representing approximately 87.6 percent of the Company’s common stock outstanding as of the May 8, 2025 record date.

    Below are the final voting results certified by Broadridge Financial Solutions, Inc., the inspector of election, for the proposals considered and voted upon at the Annual Meeting. Each of these proposals were described in detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2025.

    Proposal 1 — Election of three Class II Directors to serve until the 2028 annual meeting of stockholders, and until their respective successors have been duly elected and qualified.

     

         FOR      WITHHOLD      BROKER
    NON-VOTE
     

    Bruno Lucidi

         46,640,587        12,559,084        15,781,736  

    Polly Murphy, DVM, PhD

         41,184,263        18,015,408        15,781,736  

    Bruce Polsky, MD, MACP, FIDSA

         46,597,653        12,602,018        15,781,736  

    Proposal 2 — Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025

     

    FOR

     

    AGAINST

     

    ABSTAIN

     

    BROKER
    NON-VOTE

    73,766,274

      1,192,659   22,474   0

    Proposal 3 — Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers.

     

    FOR

     

    AGAINST

     

    ABSTAIN

     

    BROKER
    NON-VOTE

    46,450,302

      12,107,029   642,340   15,781,736

    Based upon the foregoing votes, Bruno Lucidi, Dr. Polly Murphy and Dr. Bruce Polsky were elected as Class II directors and Proposals 2 and 3 were approved.

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        ATEA PHARMACEUTICALS, INC.
    Date: June 20, 2025     By:  

    /s/ Andrea Corcoran

          Andrea Corcoran
          Chief Financial Officer and Executive Vice President, Legal and Secretary
    Get the next $AVIR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AVIR

    DatePrice TargetRatingAnalyst
    8/13/2024$2.00 → $6.88Underweight → Equal-Weight
    Morgan Stanley
    8/10/2023Neutral → Underweight
    JP Morgan
    3/2/2022$10.00 → $8.00Neutral
    JP Morgan
    3/1/2022$10.00 → $9.00Market Perform
    SVB Leerink
    2/16/2022$11.00 → $10.00Market Perform
    SVB Leerink
    1/6/2022$14.00 → $7.00Equal-Weight → Underweight
    Morgan Stanley
    11/18/2021Outperform → Mkt Perform
    SVB Leerink
    11/18/2021$11.00Outperform → Market Perform
    SVB Leerink
    More analyst ratings

    $AVIR
    SEC Filings

    See more
    • SEC Form 8-K filed by Atea Pharmaceuticals Inc.

      8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)

      6/20/25 5:16:20 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Atea Pharmaceuticals Inc.

      SCHEDULE 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      5/14/25 6:21:56 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Atea Pharmaceuticals Inc.

      10-Q - Atea Pharmaceuticals, Inc. (0001593899) (Filer)

      5/12/25 4:45:23 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Berger Franklin M converted options into 29,600 shares, increasing direct ownership by 6% to 506,497 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      6/24/25 6:05:09 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Duncan Barbara Gayle converted options into 29,600 shares, increasing direct ownership by 89% to 62,750 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      6/24/25 6:05:09 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Murphy Polly A. converted options into 29,600 shares, increasing direct ownership by 52% to 86,045 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      6/24/25 6:05:11 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Berger Franklin M bought $81,498 worth of shares (25,000 units at $3.26), increasing direct ownership by 6% to 476,897 units (SEC Form 4)

      4/A - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      1/17/25 2:30:36 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Berger Franklin M decreased direct ownership by 1% to 476,897 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      1/17/25 8:03:19 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $AVIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

      C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect HCV Infection Remains a Significant Global Health Burden, with Approximately 50 Million People Infected, Including up to 4 Million in US BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, t

      6/24/25 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential Best-in-Class Profile Presented at European Association for the Study of the Liver (EASL) Congress 2025 Virtual Investor Event with Key Opinion Leader Insights on HCV to be Held May 14, 2025, at 10:00 AM ET BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results fo

      5/12/25 4:11:14 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

              Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low Risk for Drug-Drug Interactions with Regimen When Co-Administered with Standard HIV Treatment Regimen Bemnifosbuvir Was Generally Safe and Well Tolerated with No Dose Adjustment Neededin Phase 1 Studies in Participants with Hepatic or Renal Impairment Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 BOSTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the d

      5/7/25 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Atea Pharmaceuticals from Underweight to Equal-Weight and set a new price target of $6.88 from $2.00 previously

      8/13/24 7:25:26 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals downgraded by JP Morgan

      JP Morgan downgraded Atea Pharmaceuticals from Neutral to Underweight

      8/10/23 6:17:18 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan reiterated coverage on Atea Pharmaceuticals with a new price target

      JP Morgan reiterated coverage of Atea Pharmaceuticals with a rating of Neutral and set a new price target of $8.00 from $10.00 previously

      3/2/22 10:09:39 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    Leadership Updates

    Live Leadership Updates

    See more
    • Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

      BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H. Berman, Ph.D. to its Board of Directors (the "Board"). Dr. Berman will serve as a non-voting observer to the Board through Atea's 2025 Annual Meeting of Stockholders when he will join the Board as a full voting member. "We are pleased to welcome Howard Berman to the Atea Board," said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea. "We look forward to benefitting from

      4/17/25 7:00:00 AM ET
      $AVIR
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

      BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

      2/24/25 7:00:00 AM ET
      $AVIR
      $LQDA
      $KDMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development

      BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for severe viral diseases, today announced the appointment of Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development. Dr. Agrawal previously served as Vice President of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism at Merck & Co., Inc. "We are delighted to welcome Nancy to the Atea team. Her broad scientific and managerial experience in both drug discovery and drug development spanning across multiple therapeutic areas at Merck, will enrich our scientific and c

      2/10/22 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    Financials

    Live finance-specific insights

    See more
    • Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential Best-in-Class Profile Presented at European Association for the Study of the Liver (EASL) Congress 2025 Virtual Investor Event with Key Opinion Leader Insights on HCV to be Held May 14, 2025, at 10:00 AM ET BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results fo

      5/12/25 4:11:14 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

      Panel to Discuss Current Challenges Encountered by Patients with HCV, Results from Atea's Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers and Patients Event to Replace Atea's First Quarter 2025 Earnings Conference Call; Quarterly Calls to Resume with Second Quarter 2025 Financial Results BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced it will virtually host a hepatitis C virus (HCV) key opi

      5/1/25 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV) Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025 Conference Call at 4:30 pm ET Today BOSTON, March 06, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. "I am pleased to share that we recently had a successful End-of-Phase 2 meeting with

      3/6/25 4:05:00 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

      SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      11/15/24 10:34:54 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

      SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      11/12/24 9:50:14 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      2/15/24 11:35:08 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care